Please assess the completion status of the following clinical trial:

Trial Title: Assessment of Cardiotoxicity After Chemotherapy for Breast Cancer by Cardio-vascular Magnetic Resonance (MR)

Study Design Characteristics:
- Allocation: None
- Intervention Model: None
- Observational Model: COHORT
- Primary Purpose: None
- Time Perspective: PROSPECTIVE
- Masking: None
- Phase: None
- Number of Arms: None

Eligibility Criteria:
Inclusion Criteria:~* First-time diagnosis of breast cancer~* Planned chemotherapy with anthracyclines and / or Trastuzumab~* Ability to give informed consent~Exclusion Criteria:~* Contra-indications for CMR study (e.g. implanted pacemaker / ICD; severe renal impairment (GFR\< 35 ml/min); severe claustrophobia)~* Previous history of non-ischemic cardiomyopathies or myocardial inflammation~* Inability to give informed consent~* Concomitant drug abuse (e.g. cocaine)~* Expected life expectancy \< 6 months

- Gender: FEMALE
- Minimum Age: None
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- I (Type: None): Consecutive patients with first-time diagnosis of metastatic breast cancer undergoing chemotherapy with anthracyclines and/or trastuzumab.

Based on this trial design, predict the completion outcome and termination type (if applicable).